Craig-Hallum initiated coverage of Aclaris Therapeutics (ACRS) with a Buy rating and $10 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRS:
- Aclaris Therapeutics reports ‘positive’ results from ATI-2138
- Aclaris Therapeutics initiates Phase 1b proof-of-concept trial of ATI-052
- Aclaris Therapeutics Expands Inflammation and Immunology Pipeline Strategy
- Aclaris advances ATI-052 after positive Phase 1a results
- Aclaris Therapeutics reports ‘positive’ results from Phase 1a trial of ATI-052